DOI: 10.1128/AAC.01142-19
Article Information
PubMed
Published By
History
- Received June 3, 2019
- Returned for modification June 26, 2019
- Accepted July 2, 2019
- Published online August 23, 2019.
Copyright & Usage
Copyright © 2019 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (July 15, 2019).
- You are viewing the most recent version of this article.
Author Information
- aCollaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA
- bDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA
- cInstitutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, Texas, USA
- dDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA
- eSealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas, USA
- fBioscience Division, SRI International, Menlo Park, California, USA
- Address correspondence to Peter B. Madrid, peter.madrid{at}sri.com, or Sean Ekins, sean{at}collaborationspharma.com.
Citation Lane TR, Comer JE, Freiberg AN, Madrid PB, Ekins S. 2019. Repurposing quinacrine against Ebola virus infection in vivo. Antimicrob Agents Chemother 63:e01142-19. https://doi.org/10.1128/AAC.01142-19.
